Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

A tailored approach to fusion transcript identification increases diagnosis of rare inherited disease.

Tytuł:
A tailored approach to fusion transcript identification increases diagnosis of rare inherited disease.
Autorzy:
Oliver GR; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Tang X; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Schultz-Rogers LE; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Vidal-Folch N; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.
Jenkinson WG; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Schwab TL; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States of America.
Gaonkar K; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Cousin MA; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Nair A; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Basu S; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Chanana P; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Oglesbee D; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.; Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota, United States of America.
Klee EW; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.; Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, United States of America.
Źródło:
PloS one [PLoS One] 2019 Oct 02; Vol. 14 (10), pp. e0223337. Date of Electronic Publication: 2019 Oct 02 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Genetic Association Studies*/methods
Genetic Predisposition to Disease*
Genetic Diseases, Inborn/*diagnosis
Genetic Diseases, Inborn/*genetics
Mutant Chimeric Proteins/*genetics
Rare Diseases/*diagnosis
Rare Diseases/*genetics
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Female ; Genetic Markers ; Humans ; Infant ; Inheritance Patterns ; Male ; Middle Aged ; Phenotype ; Workflow ; Young Adult
References:
Mol Genet Genomic Med. 2019 Mar;7(3):e00560. (PMID: 30632316)
Hum Genet. 2005 Jun;117(1):1-8. (PMID: 15834588)
Nat Rev Genet. 2016 May;17(5):257-71. (PMID: 26996076)
Hum Mol Genet. 2001 Apr 1;10(8):797-806. (PMID: 11285245)
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33. (PMID: 27322403)
Int J Genomics. 2017;2017:4798474. (PMID: 28630856)
Genes (Basel). 2018 Jan 16;9(1):null. (PMID: 29337901)
Psychiatry Res. 2015 Feb 28;225(3):268-75. (PMID: 25595337)
J Clin Immunol. 2018 Apr;38(3):307-319. (PMID: 29671115)
Nat Genet. 2012 Jul 01;44(8):881-5. (PMID: 22751096)
Autism Res. 2014 Apr;7(2):254-63. (PMID: 24634087)
Sci Rep. 2016 Feb 10;6:21597. (PMID: 26862001)
Am J Hum Genet. 2014 Aug 7;95(2):143-61. (PMID: 25065914)
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8. (PMID: 26582918)
Nucleic Acids Res. 2002 Jan 1;30(1):52-5. (PMID: 11752252)
Genome Res. 2006 Jan;16(1):30-6. (PMID: 16344562)
Nat Med. 2019 Jun;25(6):911-919. (PMID: 31160820)
Mol Psychiatry. 2010 Jul;15(7):669-72. (PMID: 20351725)
Eur J Med Genet. 2008 Jul-Aug;51(4):292-302. (PMID: 18424204)
Hum Mutat. 2011 Feb;32(2):E2036-49. (PMID: 21280143)
Cell Rep. 2014 Dec 24;9(6):2001-10. (PMID: 25497101)
Eur J Hum Genet. 2018 Dec;26(12):1797-1809. (PMID: 30097616)
Sci Transl Med. 2017 Apr 19;9(386):. (PMID: 28424332)
Genet Med. 2015 May;17(5):405-24. (PMID: 25741868)
Cancer Discov. 2013 Dec;3(12):1394-403. (PMID: 24089019)
Eur J Hum Genet. 2013 Jan;21(1):112-4. (PMID: 22669415)
Am J Hum Genet. 1997 Sep;61(3):520-8. (PMID: 9326317)
Hum Mutat. 2009 Dec;30(12):1620-7. (PMID: 19810120)
J Cancer. 2015 May 01;6(6):555-67. (PMID: 26000048)
Biopreserv Biobank. 2015 Oct;13(5):311-9. (PMID: 26484571)
Am J Med Genet B Neuropsychiatr Genet. 2015 Dec;168(8):669-77. (PMID: 26290131)
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761. (PMID: 29155950)
Nucleic Acids Res. 2016 Apr 7;44(6):2859-72. (PMID: 26837576)
Am J Hum Genet. 2013 Oct 3;93(4):697-710. (PMID: 24094746)
Clin Genet. 2016 Mar;89(3):275-84. (PMID: 26283276)
BMC Bioinformatics. 2016 Dec 7;17(1):518. (PMID: 27923364)
Genome Biol. 2011 Aug 11;12(8):R72. (PMID: 21835007)
Int J Mol Sci. 2017 Mar 28;18(4):. (PMID: 28350330)
Cytogenet Genome Res. 2011;132(3):135-43. (PMID: 21042007)
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):149-160. (PMID: 29357299)
Hum Mutat. 2000;15(3):220-7. (PMID: 10679937)
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655. (PMID: 29145629)
Hum Genet. 2006 Mar;119(1-2):162-8. (PMID: 16395596)
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368. (PMID: 27924014)
N Engl J Med. 2013 Oct 17;369(16):1502-11. (PMID: 24088041)
Sci Rep. 2013;3:1346. (PMID: 23439489)
BMC Genet. 2013 Jul 06;14:61. (PMID: 23829304)
J Mol Biol. 1990 Oct 5;215(3):403-10. (PMID: 2231712)
Genet Med. 2016 Jul;18(7):678-85. (PMID: 26633545)
J Med Genet. 2013 Aug;50(8):543-51. (PMID: 23749989)
Nat Commun. 2017 Jun 12;8:15824. (PMID: 28604674)
Eur J Hum Genet. 2003 Jul;11(7):527-34. (PMID: 12825074)
J Inherit Metab Dis. 2018 May;41(3):525-532. (PMID: 29372369)
Substance Nomenclature:
0 (Genetic Markers)
0 (Mutant Chimeric Proteins)
Entry Date(s):
Date Created: 20191003 Date Completed: 20200316 Latest Revision: 20200316
Update Code:
20240104
PubMed Central ID:
PMC6774566
DOI:
10.1371/journal.pone.0223337
PMID:
31577830
Czasopismo naukowe
Background: RNA sequencing has been proposed as a means of increasing diagnostic rates in studies of undiagnosed rare inherited disease. Recent studies have reported diagnostic improvements in the range of 7.5-35% by profiling splicing, gene expression quantification and allele specific expression. To-date however, no study has systematically assessed the presence of gene-fusion transcripts in cases of germline disease. Fusion transcripts are routinely identified in cancer studies and are increasingly recognized as having diagnostic, prognostic or therapeutic relevance. Isolated reports exist of fusion transcripts being detected in cases of developmental and neurological phenotypes, and thus, systematic application of fusion detection to germline conditions may further increase diagnostic rates. However, current fusion detection methods are unsuited to the investigation of germline disease due to performance biases arising from their development using tumor, cell-line or in-silico data.
Methods: We describe a tailored approach to fusion candidate identification and prioritization in a cohort of 47 undiagnosed, suspected inherited disease patients. We modify an existing fusion transcript detection algorithm by eliminating its cell line-derived filtering steps, and instead, prioritize candidates using a custom workflow that integrates genomic and transcriptomic sequence alignment, biological and technical annotations, customized categorization logic, and phenotypic prioritization.
Results: We demonstrate that our approach to fusion transcript identification and prioritization detects genuine fusion events excluded by standard analyses and efficiently removes phenotypically unimportant candidates and false positive events, resulting in a reduced candidate list enriched for events with potential phenotypic relevance. We describe the successful genetic resolution of two previously undiagnosed disease cases through the detection of pathogenic fusion transcripts. Furthermore, we report the experimental validation of five additional cases of fusion transcripts with potential phenotypic relevance.
Conclusions: The approach we describe can be implemented to enable the detection of phenotypically relevant fusion transcripts in studies of rare inherited disease. Fusion transcript detection has the potential to increase diagnostic rates in rare inherited disease and should be included in RNA-based analytical pipelines aimed at genetic diagnosis.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies